The Relationship Between Total Lesion Activity on ¹⁸F Choline Positron Emission Tomography-Computed Tomography and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Bone Metastases Treated with ²²³Radium.

Cancer biotherapy & radiopharmaceuticals Pub Date : 2020-08-01 Epub Date: 2020-02-28 DOI:10.1089/cbr.2019.3188

Luca Filippi, Pietro Basile, Orazio Schillaci, Oreste Bagni

{"title":"The Relationship Between Total Lesion Activity on 18F Choline Positron Emission Tomography-Computed Tomography and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Bone Metastases Treated with 223Radium.","authors":"Luca Filippi, Pietro Basile, Orazio Schillaci, Oreste Bagni","doi":"10.1089/cbr.2019.3188","DOIUrl":null,"url":null,"abstract":"The aim of the study was to assess the correlation between metabolic response measured through positron emission tomography-computed tomography (PET-CT) with 18F choline (18F FCH) and overall survival (OS) in patients affected by bone lesions from metastatic castration-resistant prostate cancer treated with 223Ra dichloride. Eleven subjects were subjected to PET-CT with 18F FCH before and 1 month after 223Ra treatment. Reduction in total lesion activity (ΔTLA) between pretreatment and post-treatment scan was determined and patients were divided into responders (ΔTLA >50%) and nonresponders (ΔTLA <50%). The OS of the entire cohort was 12.7 ± 3.8 months. Kaplan-Meier analysis showed that responders presented a significantly longer survival than nonresponders (16.5 ± 1.9 months vs. 10.5 ± 0.9 months, p < 0.05). Reduction in TLA after 223Ra treatment seems to be correlated with a trend toward a longer survival.","PeriodicalId":518937,"journal":{"name":"Cancer biotherapy & radiopharmaceuticals","volume":" ","pages":"398-403"},"PeriodicalIF":0.0000,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cbr.2019.3188","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer biotherapy & radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/cbr.2019.3188","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/2/28 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 5

Abstract

The aim of the study was to assess the correlation between metabolic response measured through positron emission tomography-computed tomography (PET-CT) with ¹⁸F choline (¹⁸F FCH) and overall survival (OS) in patients affected by bone lesions from metastatic castration-resistant prostate cancer treated with ²²³Ra dichloride. Eleven subjects were subjected to PET-CT with ¹⁸F FCH before and 1 month after ²²³Ra treatment. Reduction in total lesion activity (ΔTLA) between pretreatment and post-treatment scan was determined and patients were divided into responders (ΔTLA >50%) and nonresponders (ΔTLA <50%). The OS of the entire cohort was 12.7 ± 3.8 months. Kaplan-Meier analysis showed that responders presented a significantly longer survival than nonresponders (16.5 ± 1.9 months vs. 10.5 ± 0.9 months, p < 0.05). Reduction in TLA after ²²³Ra treatment seems to be correlated with a trend toward a longer survival.

查看原文本刊更多论文

223镭治疗去势抵抗性前列腺癌骨转移患者18F胆碱正电子发射断层扫描-计算机断层扫描病灶总活动性与临床预后的关系

该研究的目的是评估通过正电子发射断层扫描-计算机断层扫描(PET-CT)测量的代谢反应与223Ra二氯化治疗的转移性去势抵抗性前列腺癌骨病变患者的总生存期(OS)之间的相关性。11名受试者在223Ra治疗前和治疗后1个月分别用18F FCH进行PET-CT检查。测定了治疗前和治疗后扫描的总病变活动性降低(ΔTLA)，并将患者分为有反应者(ΔTLA >50%)和无反应者(ΔTLA p 223Ra治疗似乎与更长的生存趋势相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer biotherapy & radiopharmaceuticals

自引率

0.00%

发文量